Small Bispecific Affinity Proteins for Simultaneous Target Binding and Albumin-Associated Half-Life Extension.

Published on Jan 4, 2021in Molecular Pharmaceutics4.321
· DOI :10.1021/ACS.MOLPHARMACEUT.0C00975
Emma von Witting4
Estimated H-index: 4
(KTH: Royal Institute of Technology),
Sarah Lindbo8
Estimated H-index: 8
(KTH: Royal Institute of Technology)
+ 8 AuthorsSophia Hober41
Estimated H-index: 41
(KTH: Royal Institute of Technology)
Sources
Abstract
Albumin-binding fusion partners are frequently used as a means for the in vivo half-life extension of small therapeutic molecules that would normally be cleared very rapidly from circulation. However, in applications where small size is key, fusion to an additional molecule can be disadvantageous. Albumin-derived affinity proteins (ADAPTs) are a new type of scaffold proteins based on one of the albumin-binding domains of streptococcal protein G, with engineered binding specificities against numerous targets. Here, we engineered this scaffold further and showed that this domain, as small as 6 kDa, can harbor two distinct binding surfaces and utilize them to interact with two targets simultaneously. These novel ADAPTs were developed to possess affinity toward both serum albumin as well as another clinically relevant target, thus circumventing the need for an albumin-binding fusion partner. To accomplish this, we designed a phage display library and used it to successfully select for single-domain bispecific binders toward a panel of targets: TNFα, prostate-specific antigen (PSA), C-reactive protein (CRP), renin, angiogenin, myeloid-derived growth factor (MYDGF), and insulin. Apart from successfully identifying bispecific binders for all targets, we also demonstrated the formation of the ternary complex consisting of the ADAPT together with albumin and each of the five targets, TNFα, PSA, angiogenin, MYDGF, and insulin. This simultaneous binding of albumin and other targets presents an opportunity to combine the advantages of small molecules with those of larger ones allowing for lower cost of goods and noninvasive administration routes while still maintaining a sufficient in vivo half-life.
📖 Papers frequently viewed together
24 Citations
20142.74PLOS ONE
6 Authors (Johan Nilvebrant, ..., Sophia Hober)
32 Citations
24 Citations
References31
Newest
#1Mathias Uhlén (KI: Karolinska Institutet)H-Index: 126
#2Max J. Karlsson (KTH: Royal Institute of Technology)H-Index: 5
Last. Åsa Sivertsson (KTH: Royal Institute of Technology)H-Index: 15
view all 53 authors...
The proteins secreted by human cells (collectively referred to as the secretome) are important not only for the basic understanding of human biology but also for the identification of potential targets for future diagnostics and therapies. Here, we present a comprehensive analysis of proteins predicted to be secreted in human cells, which provides information about their final localization in the human body, including the proteins actively secreted to peripheral blood. The analysis suggests that...
48 CitationsSource
#1Hao Liu (KTH: Royal Institute of Technology)H-Index: 4
#1Hao Liu (KTH: Royal Institute of Technology)H-Index: 22
Last. Torbjörn Gräslund (KTH: Royal Institute of Technology)H-Index: 21
view all 9 authors...
Potent and specific fusion toxins consisting of a HER2-binding ABD-derived affinity protein (ADAPT), fused to truncated versions of Pseudomonas exotoxin A
5 CitationsSource
#1Alessandro Zorzi (EPFL: École Polytechnique Fédérale de Lausanne)H-Index: 5
#2Sara Linciano (Ca' Foscari University of Venice)H-Index: 2
Last. Alessandro Angelini (Ca' Foscari University of Venice)H-Index: 18
view all 3 authors...
Peptides and small protein scaffolds are gaining increasing interest as therapeutics. Similarly to full-length antibodies, they can bind a target with a high binding affinity and specificity while remaining small enough to diffuse into tissues. However, despite their numerous advantages, small biotherapeutics often suffer from a relatively short circulating half-life, thus requiring frequent applications that ultimately restrict their ease of use and user compliance. To overcome this limitation,...
26 CitationsSource
#1Rajiv Bajracharya (Dongguk University)H-Index: 4
#2Jae Geun Song (Dongguk University)H-Index: 7
Last. Hyo-Kyung Han (Dongguk University)H-Index: 30
view all 4 authors...
Abstract Advancements in biotechnology and protein engineering expand the availability of various therapeutic proteins including vaccines, antibodies, hormones, and growth factors. In addition, protein drugs hold many therapeutic advantages over small synthetic drugs in terms of high specificity and activity. This has led to further R&D investment in protein-based drug products and an increased number of drug approvals for therapeutic proteins. However, there are many biological and biopharmaceu...
29 CitationsSource
#1António L. Grilo (Imperial College London)H-Index: 4
#2Athanasios Mantalaris (Imperial College London)H-Index: 36
The monoclonal antibody (mAb) market has changed rapidly in the past 5 years: it has doubled in size, becoming dominated by fully human molecules, launched bispecific molecules, and faced competition from biosimilars. We summarize the market in terms of therapeutic applications, type and structure of mAbs, dominant companies, manufacturing locations, and emerging markets.
128 CitationsSource
#1Javad Garousi (Uppsala University)H-Index: 13
#2Sarah Lindbo (KTH: Royal Institute of Technology)H-Index: 8
Last. Sophia Hober (KTH: Royal Institute of Technology)H-Index: 41
view all 11 authors...
Abstract ADAPTs are small engineered non-immunoglobulin scaffold proteins, which have demonstrated very promising features as vectors for radionuclide tumour targeting. Radionuclide imaging of human epidermal growth factor 2 (HER2) expression in vivo might be used for stratification of patients for HER2-targeting therapies. ADAPT6, which specifically binds to HER2, has earlier been shown to have very promising features for in vivo targeting of HER2 expressing tumours. In this study we tested the...
11 CitationsSource
55 CitationsSource
#1Zhe Li (UB: University at Buffalo)H-Index: 5
#2Ben-Fillippo Krippendorff (Hoffmann-La Roche)H-Index: 12
Last. Dhaval K. Shah (UB: University at Buffalo)H-Index: 18
view all 6 authors...
Biodistribution coefficients (BC) allow estimation of the tissue concentrations of proteins based on the plasma pharmacokinetics. We have previously established the BC values for monoclonal antibodies. Here, this concept is extended by development of a relationship between protein size and BC values. The relationship was built by deriving the BC values for various antibody fragments of known molecular weight from published biodistribution studies. We found that there exists a simple exponential ...
52 CitationsSource
#1Javad Garousi (Uppsala University)H-Index: 13
#2Sarah Lindbo (KTH: Royal Institute of Technology)H-Index: 8
Last. Sophia Hober (KTH: Royal Institute of Technology)H-Index: 41
view all 10 authors...
Small engineered scaffold proteins have attracted attention as probes for radionuclide-based molecular imaging. One class of these imaging probes, termed ABD-Derived Affinity ProTeins (ADAPT), have been created using the albumin-binding domain (ABD) of streptococcal protein G as a stable protein scaffold. In this study, we report the development of a clinical lead probe termed ADAPT6 that binds HER2, an oncoprotein overexpressed in many breast cancers that serves as a theranostic biomarker for s...
29 CitationsSource
#1Anders Christiansen (DTU: Technical University of Denmark)H-Index: 4
#2Jens Vindahl Kringelum (DTU: Technical University of Denmark)H-Index: 8
Last. Martin DufvaH-Index: 32
view all 13 authors...
Phage display is a prominent screening technique with a multitude of applications including therapeutic antibody development and mapping of antigen epitopes. In this study, phages were selected based on their interaction with patient serum and exhaustively characterised by high-throughput sequencing. A bioinformatics approach was developed in order to identify peptide motifs of interest based on clustering and contrasting to control samples. Comparison of patient and control samples confirmed a ...
47 CitationsSource
Cited By0
Newest